News | April 24, 2026
Boston Scientific surges into 2026 with double-digit sales growth & record quarterly profit jump
Growth was broad-based across segments
Growth was broad-based across segments
Penumbra projects fourth-quarter revenue growth of 21.4% to 22.0%, with full-year 2025 revenue expected to reach approximately $1.4 billion
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
The transaction is anticipated to close in the first quarter of 2022
Health innovations are viewed more positively than food and agricultural technologies
Move comes amid rising regulatory pressures
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Subscribe To Our Newsletter & Stay Updated
